

## Symposium

### *New Perspectives in Her2 Management*

Siófok - May 18<sup>th</sup>, 2012

2<sup>nd</sup> Pannonia Congress of Pathology

Lecture Room: Toscana I

- Invitation*  
**Invitation**
- 15:35 – 15:40 *Welcome and Introduction* - **J.Razga & R. Havranek**
- 15:40 – 16:00 Her2 Assessment in Gastric Cancer - **Dr. Nicolas Binder**
- 16:00 – 16:15 IQ-FISH The Fight Against Time - **G. Echezarreta**
- 16:10 – 16:25 Demonstration of HER2 gene copy alterations using the high-speed IQFISH test in breast carcinoma - **Katalin Hegyi**
- 16:25 – 16:35 *Discussion and Closing* - **J.Razga & R.Havranek**

#### Topics

The choice and the efficacy of pharmacologic treatment in oncology is driven by the correct patient selection based on the evaluation of presence or absence of specific biomarkers.

This new concept has requested pathologists, as key players in the diagnostic process, to draw special attention not only to the choice of the diagnostic test (as IHC and FISH/CISH) that identifies the patients who are likely to benefit from these targeted approach, but also to pay special attention to interpretation and scoring guidelines.

In this contest, a fast and accurate answer to oncologist is appreciated. Dako has recently released a new FISH technology, Her2 IQFISH, that allowed to get Her2 gene status in only three hours and a half, which translate into a faster report to oncologists and consequently an earlier initiation of the proper treatment.

#### Speakers

- **Nicolas Binder, PhD** - Sozialmedizinisches Zentrum Süd- Kaiser Franz Josef Spital, Austria
- **Katalin Hegyi** - University of Debrecen, Hungary
- **Gemma Echezarreta** - Application Specialist, DAKO European Distributor Markets
- **Rosmarie Havranek** - Country Manager, Dako Austria
- **Jakub Razga** - Business Manager, DAKO European Distributor Markets

*Invitation*  
**Invitation**